M&AHealthcareSIGNED
Novo Nordisk Acquires Global Rights to Chinese Obesity Pill for $2.26 Billion
Value
$2.3Bn
Acquirer
Novo Nordisk
Target
Hengrui (rights to experimental obesity pill)
Novo Nordisk has secured global rights to an experimental obesity pill developed by China's Hengrui. The Danish company will be able to develop, manufacture, and market the drug outside of Asia.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.